The Harvard-MIT genomic science institute stays mute on how it will assert control over the tools expected to speed cures and change gene therapy.
The most extensive collaboration between the patient social network and a drug company to-date is likely to be just the first of its kind.
Many are eager to trot out GMOs as the answer to our food problems. But lower-tech alternatives work better.
Designer changes in the first artificial yeast chromosome could help advance synthetic biology.
A low-cost microscope made from folded paper and a cheap lens could revolutionize education and health care in the developing world.
High-tech blood tests should replace ultrasound and other methods as the primary tools for screening for Down syndrome, argue researchers.
Now that genomes can be sequenced for $1,000, more patients can benefit, says Howard Jacob.
Claims for a new, simple, technique to create stem cells.
New method could help scientists understand neural circuits and tumor biology.
Following the Supreme Court's rejection of gene patents, the U.S. proposes steep cuts to reimbursements for tests that detect breast cancer genes.